Log In
Print
BCIQ
Print
Print this Print this
 

Northera, droxidopa

  Manage Alerts
Collapse Summary General Information
Company Sumitomo Dainippon Pharma Co. Ltd.
DescriptionOrally available synthetic precursor of norepinephrine
Molecular Target
Mechanism of ActionNA
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationHypotension
Indication DetailsTreat intradialytic hypotension (IDH); Treat neurogenic orthostatic hypotension (NOH); Treat orthostatic hypotension; Treat symptomatic neurogenic orthostatic hypotension (NOH) associated with Parkinson's disease (PD)
Regulatory Designation

U.S. - Accelerated Approval (Treat neurogenic orthostatic hypotension (NOH));
U.S. - Fast Track (Treat neurogenic orthostatic hypotension (NOH));
U.S. - Orphan Drug (Treat neurogenic orthostatic hypotension (NOH));
U.S. - Priority Review (Treat neurogenic orthostatic hypotension (NOH));
U.S. - Special Protocol Assessment (Treat neurogenic orthostatic hypotension (NOH));
EU - Orphan Drug (Treat orthostatic hypotension)

Partner

H. Lundbeck A/S


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today